GlassScriptPhysician profile
Keith Christopher Summa
NPI 1780074476
$6,836.51
in general payments reported to CMS, 2019-2025
10 companies · $35.58 in 2025
The $35.58 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $99.00 · 2021: $152 · 2022: $181 · 2023: $6,282 · 2024: $87.37 · 2025: $35.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,490 · Travel and Lodging: $658 · Food and Beverage: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,490.00 |
| Travel and Lodging | $658.37 |
| Food and Beverage | $256.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $5,555.84 | 2023 | |
| Celgene Corporation | $811.37 | 2022-2023 | Zeposia |
| Janssen Scientific Affairs, LLC | $146.93 | 2021-2025 | Tremfya |
| Janssen Biotech, INC. | $127.01 | 2020-2021 | |
| Celltrion USA INC. | $65.86 | 2024 | Vegzelma |
| Abbvie INC. | $45.30 | 2023 | Rinvoq, Skyrizi |
| Mauna Kea Technologies, INC. | $37.17 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.83 | 2022-2024 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.20 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Summa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.